Patent EP0187009A2 successfully refreshed from Google Patents.
EP0187009A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Compounds and compositions having anti-inflammatory and analgesic activity
Assignee: Procter and Gamble Co
•
Filing: 1985-12-16
•
Granted: —
•
Expires: 2005-12-16
Abstract
Abstract Trienamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: <CHEM> wherein R is a straight or branched chain tri-unsaturated fatty acid amide having from 14 to 24 carbon atoms exhibit anti-inflammatory and analgesic activity when administered to humans and lower animals.
Inventors
- 👤 John Michael Janusz
- 👤 Maurice Edward Loomans
- 👤 Thomas Robert Lahann
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 18:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/165; A61P; A61P25/00; A61P25/04; A61P29/00; C; C07; C07C; C07C233/00; C07C233/01; C07C233/16
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
28 words
Trienamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: wherein R is a straight or branched chain tri-unsaturated fatty acid amide having from 14 to 24 carbon atoms.
Claim 2
Dependent Claim
28 words
Trienamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: wherein R is a straight or branched chain tri-unsaturated fatty acid amide having from 14 to 24 carbon atoms.
Claim 3
Dependent Claim
29 words
Trienamide compounds, and pharmacutically-acceptable. salts thereof, according to Claim 1, wherein R is a straight or branched chain tri-unsaturated fatty acid amide having from 18 to 20 carbon atoms.
Claim 4
Dependent Claim
20 words
Trienamide compounds, and pharmaceutically-acceptable salts thereof, according to Claim 1, wherein R is a straight chain tri-unsaturated fatty acid amide.
Claim 5
Dependent Claim
27 words
Trienamide compounds, and pharmaceutically-acceptable. salts thereof, according to Claim 3, wherein R is a straight chain tri-unsaturated fatty acid amide having from 18 to 20 carbon atoms.
Claim 6
Dependent Claim
16 words
The trienamide compound, according to Claim 4, wherein said trienamide is N-vanillyl-9Z,12Z,15Z-octadecatrienamide and pharmaceutically-acceptable salts thereof.
Claim 7
Dependent Claim
16 words
The trienamide compound, according to Claim 4, wherein said trienamide is N-vanillyl-6Z,9Z,12Z-octadecatrienamide and pharmaceutically-acceptable salts thereof.
Claim 8
Dependent Claim
17 words
The trienamide compound, according to Claim 4, wherein said trienamide is N-vanillyl-11Z,14Z,17Z-eicosa- trienamide and pharmaceutically-acceptable salts thereof.
Claim 9
Dependent Claim
60 words
A composition for reducing inflammation and producing analgesia in humans or lower animals comprising: (a) a safe and effective amount of a trienamide compound of the formula wherein R is a straight or branched chain tri- unsaturated fatty acid amide having from 14 to 24 carbon atoms, or a pharmaceutically-acceptable salt thereof, or mixtures thereof; and (b) a pharmaceutically-acceptable carrier.
Claim 10
Dependent Claim
60 words
A composition for reducing inflammation and producing analgesia in humans or lower animals comprising: (a) a safe and effective amount of a trienamide compound of the formula wherein R is a straight or branched chain tri- unsaturated fatty acid amide having from 14 to 24 carbon atoms, or a pharmaceutically-acceptable salt thereof, or mixtures thereof; and (b) a pharmaceutically-acceptable carrier.
Claim 11
Dependent Claim
25 words
A composition, according to Claim 8, wherein R is a straight or branched chain tri-unsaturated fatty acid amide having from 18 to 20 carbon atoms.
Claim 12
Dependent Claim
16 words
A composition, according to Claim 8, wherein R is a straight chain tri-unsaturated fatty acid amide.
Claim 13
Dependent Claim
23 words
A composition, according to Claim 10, wherein R is a straight chain tri-unsaturated fatty acid amide having from 18 to 20 carbon atoms.
Claim 14
Dependent Claim
12 words
A composition, according to Claim 11, wherein said trienamide compound is N-vanillyl-9Z,12Z,15Z-octadecatrienamide.
Claim 15
Dependent Claim
12 words
A composition, according to Claim 11, wherein said trienamide compound is N-vanillyl-6Z,9Z,12Z-octadecatrienamide.
Claim 16
Dependent Claim
18 words
A composition, according to Claim 11, particularly useful for reducing inflammation, wherein said trienamide compound is N-vanillyl-11Z,14Z,17Z-eicosatri- enamide.
Claim 17
Dependent Claim
20 words
A composition, according to Claim 8, for parenteral administration, comprising at least about 90%, by weight, of said pharmaceutically-acceptable carrier.
Claim 18
Dependent Claim
21 words
A composition, according to Claim 8, for oral administration, comprising from about 25% to about 50%, by weight, of said trienamide.
Claim 19
Dependent Claim
21 words
A composition, according to Claim 8, for topical administration, comprising from about 1% to about 5%, by weight, of said trienamide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.